Trial Profile
A Phase IIb, Randomized, Placebo-Controlled, Dose-Finding Clinical Trial to Study the Safety and Efficacy of MK-8237 Using an Environmental Exposure Chamber in Subjects With House Dust Induced Allergic Rhinitis/Rhinoconjunctivitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 24 Jan 2020 USA was in planned locations of the trial, according to European Clinical Trials Database.
- 07 Mar 2016 Results at one-year after completion of a 24-Week treatment period presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 10 Jun 2015 MSD published the results of this study in The Journal of Allergy and Clinical Immunology, according to an ALK media release.